PriceTargetCut News & Analysis

Omeros (OMER) Faces CHMP Review, Price Target Cut to $33

Omeros Corp. (NASDAQ: OMER) received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its marketing authorization for narsoplimab, an antibody targeting MASP-2 for treating hematopoietic stem cell transplant-related thrombotic microangiopathy. Following this, analyst Brandon Folkes from H.C. Wainwright reduced the price target from $40 to $33, suggesting an upside of more than 233%. Despite the setback, Folkes maintained a Buy rating, emphasizing the U.S. launch as a potential key value driver for the stock. This matters for investors as it highlights both risks and potential rewards in Omeros’ future growth strategies.